April 15-16, 2024 | Orlando, USA
Raza Khan
HCA Medical City Healthcare, USA
Dr. Raza Khan holds a Bachelor of Science in Neuroscience from the University of Rochester and earned his MD with AOA honors from the University of Oklahoma College of Medicine. Currently undertaking his transitional year at the HCA Medical City Healthcare UNT-TCU GME Program, Dr. Khan is committed to pursuing advanced training in dermatology. Collaborating with Dr. Amor Khachemoune, MD, FAAD, he is actively engaged in advancing understanding within dermatology, particularly focusing on non-invasive imaging techniques. Dr. Khan has achieved acceptance for four papers in reputable publications over the past six months.
Morphea, an autoimmune progressive disorder, can significantly impact patient well-being, yet therapeutic options, though expanding, exhibit limited efficacy. A persistent challenge in disease management revolves around monitoring disease activity and gauging treatment effectiveness. To address this, various clinical assessment tools have been devised, each with its inherent limitations. The realm of imaging in morphea has undergone noteworthy expansion, with ultrasonography (US) emerging as an efficacious and cost-effective avenue for quantifying disease activity and evaluating therapeutic outcomes. However, the evidential support for its application remains equivocal. Our aim was to explore and analyze the existing evidence concerning the utility of ultrasound in the management of morphea.We conducted a comprehensive literature review using PubMed Medline to assess evidence concerning US utility in morphea management. Sixteen total studies were included in our review. Although studies presented carry their own limitations, cumulative findings indicate the potential of ultrasound, particularly when coupled with doppler, in facilitating staging, assessing disease activity, and longitudinal assessment of therapeutic efficacy in patients with morphea.